Daxor (NASDAQ:DXR) Price Target Raised to $25.00 at Ascendiant Capital Markets

Posted by Alphonse Anthony on Mar 17th, 2025

Daxor (NASDAQ:DXR – Get Free Report) had its price objective raised by investment analysts at Ascendiant Capital Markets from $24.75 to $25.00 in a research note issued on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. Ascendiant Capital Markets’ price target would indicate a potential upside of 205.62% from the company’s previous close.

Daxor Stock Performance

Shares of DXR stock opened at $8.18 on Monday. Daxor has a twelve month low of $6.55 and a twelve month high of $10.00. The business has a fifty day simple moving average of $7.79 and a 200 day simple moving average of $8.49.

Insider Activity

In related news, CEO Michael Richard Feldschuh purchased 3,360 shares of the stock in a transaction dated Monday, March 10th. The stock was bought at an average cost of $7.68 per share, for a total transaction of $25,804.80. Following the completion of the acquisition, the chief executive officer now owns 210,852 shares of the company’s stock, valued at approximately $1,619,343.36. This represents a 1.62 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 59.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Daxor

A hedge fund recently raised its stake in Daxor stock. Keyes Stange & Wooten Wealth Management LLC lifted its position in shares of Daxor Co. (NASDAQ:DXR – Free Report) by 34.8% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned about 0.30% of Daxor worth $126,000 as of its most recent filing with the Securities and Exchange Commission. 1.34% of the stock is owned by hedge funds and other institutional investors.

About Daxor

(Get Free Report)

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.